BR112018074185A2 - 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas - Google Patents
3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidasInfo
- Publication number
- BR112018074185A2 BR112018074185A2 BR112018074185-0A BR112018074185A BR112018074185A2 BR 112018074185 A2 BR112018074185 A2 BR 112018074185A2 BR 112018074185 A BR112018074185 A BR 112018074185A BR 112018074185 A2 BR112018074185 A2 BR 112018074185A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- dihydropyridazine
- diphenyl
- oxo
- carboxamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas. a presente invenção abrange os compostos de 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamida da fórmula geral (i): (i) em que r1, r2, r3, r4, r5 e r6 são como definidos neste documento, aos métodos de preparação dos compostos citados, aos compostos intermediários aplicáveis para a preparação dos compostos citados, às composições farmacêuticas e às combinações que consistem nos compostos citados para a fabricação de composições farmacêuticas para tratamento ou profilaxia de doenças, em particular de câncer ou condições com respostas imunes desreguladas ou outras desordens associadas à sinalização de ahr aberrante, como um agente isolado ou em combinação com outros agentes ativos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016083308 | 2016-05-25 | ||
| CNPCT/CN2016/083308 | 2016-05-25 | ||
| CN2017074408 | 2017-02-22 | ||
| CNPCT/CN2017/074408 | 2017-02-22 | ||
| PCT/EP2017/062355 WO2017202816A1 (en) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018074185A2 true BR112018074185A2 (pt) | 2019-03-06 |
Family
ID=58745251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074185-0A BR112018074185A2 (pt) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11040035B2 (pt) |
| EP (1) | EP3464248B1 (pt) |
| JP (1) | JP6964096B2 (pt) |
| KR (1) | KR20190009369A (pt) |
| CN (1) | CN109863140B (pt) |
| AU (1) | AU2017269870A1 (pt) |
| BR (1) | BR112018074185A2 (pt) |
| CA (1) | CA3025227A1 (pt) |
| CL (1) | CL2018003345A1 (pt) |
| CO (1) | CO2018012654A2 (pt) |
| CR (1) | CR20180556A (pt) |
| CU (1) | CU20180143A7 (pt) |
| DO (1) | DOP2018000256A (pt) |
| EA (1) | EA201892666A1 (pt) |
| EC (1) | ECSP18087725A (pt) |
| IL (1) | IL263046A (pt) |
| MA (1) | MA45087A (pt) |
| MX (1) | MX2018014443A (pt) |
| NI (1) | NI201800124A (pt) |
| PE (1) | PE20190509A1 (pt) |
| PH (1) | PH12018502472A1 (pt) |
| SG (1) | SG11201810366WA (pt) |
| SV (1) | SV2018005787A (pt) |
| TN (1) | TN2018000392A1 (pt) |
| TW (1) | TW201742859A (pt) |
| UY (1) | UY37256A (pt) |
| WO (1) | WO2017202816A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| JOP20190193A1 (ar) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
| WO2019101643A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| EP3713923B1 (en) * | 2017-11-21 | 2021-12-01 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
| US11459312B2 (en) | 2017-11-21 | 2022-10-04 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| EA037978B1 (ru) * | 2017-11-21 | 2021-06-18 | Байер Акциенгезельшафт | 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования |
| AU2019323714A1 (en) | 2018-08-24 | 2021-03-25 | Jaguahr Therapeutics Pte Ltd | Tetrahydropyridopyrimidine derivatives as AhR modulators |
| WO2020043880A1 (en) | 2018-08-31 | 2020-03-05 | Jaguahr Therapeutics Pte Ltd | Heterocyclic compounds as ahr modulators |
| CN109771437B (zh) * | 2019-03-28 | 2023-03-17 | 西安交通大学医学院第一附属医院 | 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用 |
| EP3715471A1 (en) * | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| JPWO2021020362A1 (pt) * | 2019-07-29 | 2021-02-04 | ||
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| KR20220128622A (ko) * | 2019-12-16 | 2022-09-21 | 바이엘 악티엔게젤샤프트 | Ahr-억제제 및 pd1-억제제 항체의 조합물 및 암 치료에서의 그의 용도 |
| AU2021206696A1 (en) | 2020-01-10 | 2022-08-04 | Ikena Oncology, Inc. | AHR inhibitors and uses thereof |
| EP4110778A1 (en) | 2020-02-26 | 2023-01-04 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| EP4126839A4 (en) * | 2020-03-27 | 2024-04-17 | Dong A St Co Ltd | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| CN114685426A (zh) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
| AU2022345008A1 (en) * | 2021-09-14 | 2024-04-04 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (de) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO2000009488A1 (fr) | 1998-08-14 | 2000-02-24 | Nihon Nohyaku Co., Ltd. | Derives de pyridazinone |
| EP1319659B1 (en) | 2000-09-18 | 2009-03-11 | Eisai R&D Management Co., Ltd. | Triazinones and medicinal use thereof |
| FR2847253B1 (fr) | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2847235B1 (fr) | 2002-11-20 | 2005-07-08 | Essilor Int | Emballage de protection et de calage pour objets a contour circulaire |
| WO2007058392A1 (ja) | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| US20170173008A1 (en) | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
-
2017
- 2017-05-23 MX MX2018014443A patent/MX2018014443A/es unknown
- 2017-05-23 EP EP17724833.3A patent/EP3464248B1/en active Active
- 2017-05-23 EA EA201892666A patent/EA201892666A1/ru unknown
- 2017-05-23 CA CA3025227A patent/CA3025227A1/en active Pending
- 2017-05-23 MA MA045087A patent/MA45087A/fr unknown
- 2017-05-23 BR BR112018074185-0A patent/BR112018074185A2/pt not_active IP Right Cessation
- 2017-05-23 PE PE2018003109A patent/PE20190509A1/es unknown
- 2017-05-23 CR CR20180556A patent/CR20180556A/es unknown
- 2017-05-23 CN CN201780046149.5A patent/CN109863140B/zh active Active
- 2017-05-23 SG SG11201810366WA patent/SG11201810366WA/en unknown
- 2017-05-23 TN TNP/2018/000392A patent/TN2018000392A1/en unknown
- 2017-05-23 WO PCT/EP2017/062355 patent/WO2017202816A1/en unknown
- 2017-05-23 JP JP2018561224A patent/JP6964096B2/ja active Active
- 2017-05-23 AU AU2017269870A patent/AU2017269870A1/en not_active Abandoned
- 2017-05-23 KR KR1020187037050A patent/KR20190009369A/ko not_active Application Discontinuation
- 2017-05-23 CU CU2018000143A patent/CU20180143A7/es unknown
- 2017-05-23 US US16/303,539 patent/US11040035B2/en active Active
- 2017-05-24 UY UY0001037256A patent/UY37256A/es not_active Application Discontinuation
- 2017-05-25 TW TW106117299A patent/TW201742859A/zh unknown
-
2018
- 2018-11-15 IL IL263046A patent/IL263046A/en unknown
- 2018-11-23 SV SV2018005787A patent/SV2018005787A/es unknown
- 2018-11-23 EC ECSENADI201887725A patent/ECSP18087725A/es unknown
- 2018-11-23 CO CONC2018/0012654A patent/CO2018012654A2/es unknown
- 2018-11-23 NI NI201800124A patent/NI201800124A/es unknown
- 2018-11-23 CL CL2018003345A patent/CL2018003345A1/es unknown
- 2018-11-23 PH PH12018502472A patent/PH12018502472A1/en unknown
- 2018-11-23 DO DO2018000256A patent/DOP2018000256A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SV2018005787A (es) | 2019-02-07 |
| US20200237757A1 (en) | 2020-07-30 |
| MX2018014443A (es) | 2019-04-15 |
| PH12018502472A1 (en) | 2019-09-23 |
| MA45087A (fr) | 2021-05-26 |
| CO2018012654A2 (es) | 2018-12-14 |
| IL263046A (en) | 2018-12-31 |
| US11040035B2 (en) | 2021-06-22 |
| CA3025227A1 (en) | 2017-11-30 |
| CN109863140B (zh) | 2023-02-21 |
| WO2017202816A1 (en) | 2017-11-30 |
| CR20180556A (es) | 2019-04-23 |
| KR20190009369A (ko) | 2019-01-28 |
| NI201800124A (es) | 2019-04-29 |
| EP3464248B1 (en) | 2021-09-08 |
| TW201742859A (zh) | 2017-12-16 |
| EP3464248A1 (en) | 2019-04-10 |
| CL2018003345A1 (es) | 2019-03-15 |
| AU2017269870A1 (en) | 2018-12-06 |
| CN109863140A (zh) | 2019-06-07 |
| CU20180143A7 (es) | 2019-07-04 |
| TN2018000392A1 (en) | 2020-06-15 |
| ECSP18087725A (es) | 2018-11-30 |
| SG11201810366WA (en) | 2018-12-28 |
| JP2019516744A (ja) | 2019-06-20 |
| PE20190509A1 (es) | 2019-04-10 |
| JP6964096B2 (ja) | 2021-11-10 |
| UY37256A (es) | 2018-01-02 |
| EA201892666A1 (ru) | 2019-08-30 |
| DOP2018000256A (es) | 2019-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
| BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
| BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| BR112016026809A2 (pt) | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr | |
| BR112015022462A2 (pt) | inibidores de ido | |
| BR112020008817B8 (pt) | Compostos moduladores da via de estresse integrada | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| BR112017002942A2 (pt) | compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53 | |
| EA201691514A1 (ru) | Соединения | |
| BR112019024830A2 (pt) | inibidores de bcl6 derivados de benzimidazolona | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| BR112018014525A2 (pt) | compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2672 DE 22-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |